Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
N. Scott Fine, insider at Cyclo Therapeutics
N. Scott Fine Insider Alerts

Get notified the next time N. Scott Fine buys or sells Cyclo Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

N. Scott Fine Insider Information

Scott Fine has been a Director of the Company since February 2014 and became our Chief Executive Officer on September 14, 2015. From 2004 until 2014, he was a principal at Scarsdale Equities, an investment banking firm located in New York City. Mr. Fine has been involved in investment banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. Much of his time has been focused on transactions in the healthcare and consumer products area. Mr. Fine has led global transactions in healthcare, including medical devices, generic pharmaceuticals, and genetics. He also worked with The Tempo Group of Jakarta, Indonesia.

Mr. Fine was Chairman of the Board of The Global Virus Network (GVN), and he also was the lead investment banker on the initial public offering of Green Mountain Coffee Roasters, Inc. and Central European Distribution Corporation (“CEDC”), a multi-billion-dollar alcohol company. Mr. Fine continued his involvement with CEDC serving as a director from 1996 until 2014, during which time he led the CEDC Board in its successful efforts in 2013 to restructure the company through a pre-packaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group.

Recently, Mr. Fine served as Vice Chairman and Chairman of the Restructuring Committee of Pacific Drilling from 2017 to 2018 where he successfully led the independent directors to a successful reorganization. He also served as sole director of Better Place Inc. from 2013 until 2015. In his role there, Mr. Fine successfully managed the global wind down of the company in a timely and efficient manner which was approved by both the Delaware and Israeli Courts.

Mr. Fine currently serves on the board of directors of Kenon Holdings Ltd. (NYSE: KEN).  Mr. Fine also devotes time to several non-profit organizations, including through his service on the Board of Trustees for the IWM American Air Museum in Britain.  Mr. Fine has been a guest lecturer at Ohio State University’s Moritz School of Law and Fordham University Law School.

What is N. Scott Fine's net worth?

The estimated net worth of N. Scott Fine is at least $627,223.02 as of September 15th, 2021. Mr. Fine owns 114,666 shares of Cyclo Therapeutics stock worth more than $627,223 as of November 30th. This net worth approximation does not reflect any other investments that Mr. Fine may own. Learn More.

How do I contact N. Scott Fine?

The corporate mailing address for Mr. Fine and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]

Has N. Scott Fine been buying or selling shares of Cyclo Therapeutics?

During the last ninety days, N. Scott Fine has bought $26,250.00 of Cyclo Therapeutics stock. Most recently, on Friday, November 19th, N Scott Fine bought 5,000 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $5.25 per share, with a total value of $26,250.00.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO).

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 14 times. They purchased a total of 98,501 shares worth more than $601,346.70. The most recent insider tranaction occured on November, 19th when CEO N Scott Fine bought 5,000 shares worth more than $26,250.00. Insiders at Cyclo Therapeutics own 12.3 % of the company.

Information on this page was last updated on 11/19/2021.

N. Scott Fine Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy5,000$5.25$26,250.00View SEC Filing Icon  
9/15/2021Buy5,000$6.35$31,750.00114,666View SEC Filing Icon  
See Full Table

N. Scott Fine Buying and Selling Activity at Cyclo Therapeutics

This chart shows N Scott Fine's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Read More

Today's Range

Now: $5.47
Low: $5.25
High: $5.48

50 Day Range

MA: $6.50
Low: $5.27
High: $7.34

2 Week Range

Now: $5.47
Low: $3.55
High: $17.75

Volume

101,221 shs

Average Volume

268,993 shs

Market Capitalization

$35.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Put this company on your investing radar today.